Literature DB >> 9375888

Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group.

D van der Heijde1, N Bellamy, A Calin, M Dougados, M A Khan, S van der Linden.   

Abstract

An international working group was formed to select core sets to be used as endpoints in clinical trials in ankylosing spondylitis (AS). The results of the first steps of the selection of these core sets are described. The definition of the settings for which the core set will be intended are defined. The methods used to select the core sets were a combination of literature search, nominal group discussions, and plenary discussions. The following settings were defined: disease controlling antirheumatic therapy (DC-ART), symptom modifying antirheumatic drugs (SMARD)/physical therapy, and clinical record keeping. Over 110 variables used as endpoints in AS were found in the literature. The preliminary core set for DC-ART consists of physical function, pain, spinal mobility, patient global assessment, peripheral joints/entheses, x-ray spine. The selected core set for SMARD/physical therapy includes physical function, pain, spinal mobility, spinal stiffness, and patient global assessment. The core set for clinical record keeping includes all measures of the SMARD/physical therapy core set completed by peripheral joints/entheses, and acute phase reactants. Three preliminary core sets for AS have been defined. Further research will be performed to select specific measures for all domains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375888

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  63 in total

Review 1.  New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Authors:  J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 2.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 3.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 4.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

5.  [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area].

Authors:  J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

Review 6.  Science of assessment.

Authors:  N Bellamy
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 7.  ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?

Authors:  D van der Heijde; J Braun; R Landewé; J Davis; J Sieper; S van der Linden; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

8.  ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 9.  [What is ascertained in the therapy of axial spondyloarthritis?].

Authors:  J Braun; X Baraliakos; F Heldmann; U Kiltz
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

10.  Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy.

Authors:  P V Balint; D Kane; H Wilson; I B McInnes; R D Sturrock
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.